[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345689-105":59,"doc-detail-345689-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","navigating-toxicity-in-lung-cancer-immunotherapy-challenges-and-advancesin-nano-medicine-drug-delivery","Navigating toxicity in lung cancer immunotherapy - challenges and advancesin Nano medicine drug delivery","","Lung cancer remains one of the most malignant cancers, while immunotherapy has become a major treatment pathway. Immune checkpoint inhibitors and related immunotherapeutic drugs can trigger severe immune-related adverse effects that limit therapeutic efficacy. Nanomedicine-based drug delivery systems are highlighted as a strategy to improve benefits while reducing toxicity. Nano carriers can increase bioavailability, support tumor-specific delivery, and alleviate systemic side effects, including stimuli-responsive and ligand-functionalized platforms. The review also addresses resistance mechanisms, stability and biodistribution, regulatory concerns, and emerging regulatory T-cell-directed immunotherapy approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/navigating-toxicity-in-lung-cancer-immunotherapy-challenges-and-advancesin-nano-medicine-drug-delivery/345689/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/navigating-toxicity-in-lung-cancer-immunotherapy-challenges-and-advancesin-nano-medicine-drug-delivery/345689.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is toxicity a key challenge in lung cancer immunotherapy?","Question",{"text":112,"@type":113},"Immune checkpoint inhibitors and other immunotherapeutic drugs can cause severe immune-related adverse effects, which curtail their therapeutic efficacy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does nanomedicine drug delivery aim to reduce toxicity?",{"text":117,"@type":113},"Nanomedicine-based delivery systems are designed to increase therapeutic benefits while decreasing toxicity by improving bioavailability and enabling tumor-relevant delivery environments.",{"name":119,"@type":110,"acceptedAnswer":120},"What kinds of nano carriers and platforms are discussed?",{"text":121,"@type":113},"The text describes nano carriers such as liposomes, polymeric nanoparticles, dendrites, and lipid-based systems, as well as stimuli-responsive and ligand-functionalized nano platforms for spatial control of immune responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345689,1790450811,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Jain et al. Journal of the Egyptian National Cancer Institute (2026) 38:23  \n[https://doi.org/10.1186/s43046-026-00358-7](https://doi.org/10.1186/s43046-026-00358-7)  \nJournal of the Egyptian National Cancer Institute  \nREVIEW Open Access  \nNavigating toxicity in lung cancer immunotherapy: challenges and advancesin Nano medicine drug delivery  \nRishab Jain1, Ananda Kumar Chettupalli2*, Sarad Pawar Naik Bukke3*, ShikhaYadav1, Vidya Sankarapandian4 and Ungo-Kore Hussain Yahaya3  \nAbstract  \nLung cancer is still among the most malignant cancers, with immunotherapy becoming a ground-breaking treatment option. The ICIs and other immunotherapeutic drugs usually cause severe immune-related adverse effects curtailing their therapeutic efficacy. Meeting this challenge, Nano medicine-based drug delivery systems have gained considerable interest as they hold the promise of increasing therapeutic benefits at the same time as reducing toxicity. This chapter discusses the complex balance between the effectiveness and toxicity of lung cancer immunotherapy, underlining the application of nanotechnology in maximizing drug delivery. Nano carriers like liposomes, polymeric nanoparticles, dendrites, and lipid-based systems have demonstrated the capacity to augment the bioavailability of pharmaceuticals, facilitating tumour-specific environments, and alleviating systemic side effects. Other options suggest that stimuli-responsive and ligand-functionalized Nano platforms can provide spatial control over the immune response by enhancing infiltration to the tumour site while reducing toxicity to healthy organs. On the battlegrounds of nanomedicine, inhibiting resistance mechanisms consolidated with immune checkpoint inhibitors and conventional chemotherapeutics has conferred better therapeutic responses upon the patient. Its stability, bio-distribution, and regulatory pathway concerns still challenge clinical translation. The chapter discusses recent advances in preclinical and clinical testing and describes the development of Nano medicine-based regulatory T-cell-directed immunotherapy for lung and lung-associated cancers. The problems concerning both toxicity and the application of nanotechnology for targeting therapy will open new avenues toward developing safer and more effective antitumor immunotherapeutic regimes for lung cancer.  \nKeywords Lung cancer, Immunotherapy, Nano medicine, Toxicity, Immune checkpoint inhibitors, Targeted drug delivery, Nano carriers  \n*Correspondence:  \nAnanda Kumar Chettupalli[anandphd88@gmail.com](anandphd88@gmail.com)  \nSarad Pawar Naik Bukke [drsaradpawar@kiu.ac.ug](drsaradpawar@kiu.ac.ug)  \n1Galgotias University, Greater Noida, India 2Adamas University, Kolkata, India  \n3Kampala International University, Western Campus, Ishaka-Bushenyi, Uganda  \n4Kampala International University, Kampala, Uganda  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nJain et al. Journal of the Egyptian National Cancer Institute (2026) 38:23 Page 2 of 22  \nIntroduction  \nLung cancer remains a major cancer threat worldwide because i","cbCaihLbICV3er5M","https://ap.wps.com/l/cbCaihLbICV3er5M","pdf",1723369,22,"English","# Introduction\n## Immune checkpoint pathways in lung cancer\n# Abstract\n# Keywords","[{\"question\":\"Why is toxicity a key challenge in lung cancer immunotherapy?\",\"answer\":\"Immune checkpoint inhibitors and other immunotherapeutic drugs can cause severe immune-related adverse effects, which curtail their therapeutic efficacy.\"},{\"question\":\"How does nanomedicine drug delivery aim to reduce toxicity?\",\"answer\":\"Nanomedicine-based delivery systems are designed to increase therapeutic benefits while decreasing toxicity by improving bioavailability and enabling tumor-relevant delivery environments.\"},{\"question\":\"What kinds of nano carriers and platforms are discussed?\",\"answer\":\"The text describes nano carriers such as liposomes, polymeric nanoparticles, dendrites, and lipid-based systems, as well as stimuli-responsive and ligand-functionalized nano platforms for spatial control of immune responses.\"}]","Navigating toxicity in lung cancer immunotherapy - challenges and advancesin Nano medicine drug delivery | PDF",1790058625,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f46d2c359d26d1f67ca828b85d3db668.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3a0950635054cea2b76e9fcd0a02da3.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25118123ad8ab4f7da926f64b5a6c1b7.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52f64561ca9d273743b9a774be3712b6.webp",980,1306]